New Market Report: PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer's Betaseron/Betaferon (IFNB-1b), Biogen's Avonex (IFNB-1a) and Merck's Rebif (IFNB-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Full Report Details at
- http://www.fastmr.com/prod/591930_pharmapoint_multiple_sclerosis_india_drug.aspx?afid=301

MS has a low prevalence in India, which could be due to genetics or environmental factors. However, many physicians surveyed for this report mostly use the Poser criteria to diagnose patients, given the lack of current accessibility to sensitive diagnostic tools, such as MRI. Therefore, it is possible that the current rate of MS in India is grossly underestimated, meaning a large proportion of undiagnosed MS patients are not captured and provided adequate treatment. The major drivers of growth in this market will be the launch of oral DMTs and an increase in availability of advanced diagnostic tools, which will likely lead to increased diagnosis and treatment rates over the forecast period.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope

* Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in India from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting India Multiple Sclerosis market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022